The European Commission has indicated a “strong intent” to take real-world evidence and “broader health care data” into greater consideration during regulatory and HTA decision-making in the future, according to Rebecca Lumsden, Sanofi’s head of regulatory science & policy, EU/AMEE regions.
Pharma Should Include ‘Heterogeneous Health Data’ In EU Regulatory & HTA Dossiers
Real-world data collected from a wide range of sources, such as wearable devices and public databases, can be used by pharmaceutical companies to boost their marketing authorization and health technology assessment applications, a regulatory policy expert from Sanofi says.
More from Europe
• By
Nirogacestat was one of four products scheduled for an oral explanation meeting at the European Medicines Agency this week.
• By
The European Medicines Agency is this week expected issue opinions on whether the European Commission should grant EU marketing authorization for 19 new products.
• By
Sponsors and regulatory agencies within the 27 EU member states must all be “committed” to working with the EU Clinical Trials Regulation in the most appropriate way to keep pace with other countries, including the UK where competition is heating up, says Miguel Forte, CEO of Kiji Therapeutics.
• By
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
More from Geography
• By
PhRMA questioned whether proof-of-concept studies are needed before an INTERACT meeting and said a draft guidance describing the timing of definitive toxicology studies creates confusion.
• By
Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.
• By
The European Medicines Agency is this week expected issue opinions on whether the European Commission should grant EU marketing authorization for 19 new products.